Aardvark Therapeutics files 8-K, furnishes Q3 2025 results

Aardvark Therapeutics, Inc. furnished a Form 8-K to announce a press release with financial results for the third quarter ended September 30, 2025, along with pipeline and business updates.

Rhea-AI Filing Summary

Aardvark Therapeutics, Inc. furnished a Form 8-K to announce a press release with financial results for the third quarter ended September 30, 2025, along with pipeline and business updates. The press release is provided as Exhibit 99.1, dated November 13, 2025.

The company states the information in Item 2.02 (including Exhibit 99.1) is furnished, not filed, and is not subject to Section 18 liabilities or incorporated by reference except as specifically noted. The filing also includes the Cover Page Interactive Data File as Exhibit 104. Aardvark’s common stock (AARD) is listed on The Nasdaq Stock Market LLC.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AARD disclose in its latest 8-K?

Aardvark furnished a press release reporting Q3 2025 financial results and providing pipeline and business updates as Exhibit 99.1.

What period do the results cover for AARD?

The results cover the third quarter ended September 30, 2025.

Is the information considered filed or furnished?

The Item 2.02 information (including Exhibit 99.1) is furnished, not filed, and not subject to Section 18 liabilities or incorporated by reference except as expressly provided.

What exhibits are included in AARD’s 8-K?

Exhibit 99.1: Press Release dated November 13, 2025; Exhibit 104: Cover Page Interactive Data File (Inline XBRL).

Where is AARD listed and what is its trading symbol?

Aardvark’s common stock trades on The Nasdaq Stock Market LLC under the symbol AARD.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/13/2025 - 04:20 PM Learn about SEC filing dates

false000177485700017748572025-11-132025-11-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 13, 2025

Aardvark Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-42513	82-1606367
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
4370 La Jolla Village Drive, Suite 1050
San Diego, California				92122
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 225-7696

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		AARD		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 13, 2025, Aardvark Therapeutics, Inc. issued a press release reporting its financial results for the third quarter ended September 30, 2025, and providing pipeline and business updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release, dated November 13, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			AARDVARK THERAPEUTICS, INC.
Date:	November 13, 2025	By:	/s/ Tien-Li Lee, M.D.
			Tien-Li Lee, M.D. Chief Executive Officer